Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Iron Levels on the Lungs at High Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
SLR ARM~Inclusion Criteria:~* sea level natives of lowland ancestry~* generally in good health~* detectable tricuspid regurgitation on echocardiography~Exclusion Criteria:~* any significant medical problem~* known susceptibility to high altitude pulmonary or cerebral oedema~* taking medications or iron supplements~CMS ARM~Inclusion Criteria:~* diagnosis of chronic mountain sickness~* no recent venesection therapy (within 1 year)~* detectable tricuspid regurgitation on echocardiography~Exclusion Criteria:~* any other significant medical problem

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CMS - placebo first (Type: PLACEBO_COMPARATOR): Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
- CMS - iron (Type: EXPERIMENTAL): Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
- SLR - placebo (Type: PLACEBO_COMPARATOR): Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
- SLR - iron (Type: EXPERIMENTAL): Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.

Based on this trial design, predict the completion outcome and termination type (if applicable).